Abstract |
Primary hyperparathyroidism (PHP; serum calcium 2.75 mmol/L, PTH 226 pg/ml) had been the first clinical manifestation of MEN-2A in a female patient (aged 55 years) with a mutation (Y791F, TAT-->TTT) in exon 13 of the RET proto-oncogene. The patient has a pentagastrin-induced rise in serum calcitonin (up to 57 pg/ml) considered normal for noncarriers but abnormal in family members of MEN-2 patients. This is the first case of MEN-2 due to this specific mutation with primary hyperparathyroidism as the first manifestation of the disease. In addition, the patient harbored, within the Menin gene, a polymorphism (D418D) reportedly associated with sporadic primary hyperparathyroidism. This case report indicates that molecular biological tests in MEN- 2 may only suggest a certain phenotype but cannot predict it with certainty. It may also suggest that genetic screening for MEN-2 may be advisable in patients with primary hyperparathyroidism and a borderline-high pentagastrin stimulation test, even in the absence of a positive family history.
|
Authors | H Vierhapper, S Rondot, E Schulze, L Wagner, S Hanslik, B Niederle, C Bieglmayer, K Kaserer, S Baumgartner-Parzer |
Journal | Thyroid : official journal of the American Thyroid Association
(Thyroid)
Vol. 15
Issue 11
Pg. 1303-8
(Nov 2005)
ISSN: 1050-7256 [Print] United States |
PMID | 16356097
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- DNA Primers
- MAS1 protein, human
- Proto-Oncogene Mas
- Proto-Oncogene Proteins c-ret
- Pentagastrin
- Calcium
|
Topics |
- Calcium
(blood)
- DNA Primers
- Female
- Humans
- Hyperparathyroidism
(blood, genetics, surgery)
- Middle Aged
- Multiple Endocrine Neoplasia Type 2a
(blood)
- Mutation
(physiology)
- Obesity, Morbid
(complications)
- Parathyroid Neoplasms
(surgery)
- Parathyroidectomy
- Pentagastrin
- Proto-Oncogene Mas
- Proto-Oncogene Proteins c-ret
(genetics)
- Reverse Transcriptase Polymerase Chain Reaction
|